



IN THE CLAIMS:

Claim 1 (amended): A compound, or enantiomers, stereoisomers and tautomers thereof, or pharmaceutically acceptable salts or solvates of said compound, with said compound having the general structure shown in Formula I:



Formula I

M is a moiety having a general structure shown in Formula II[or III]:



where k = 0 or 1, n = 0-5, and p = q = 0, 1 or 2;

V is a moiety selected from the group consisting of C₁-C₈ alkyl;

-(CH₂)_x-A-(CH₂)_y-; and -(CH₂)_c-A-(CH₂)_m-C(O)-N(R⁷)-(CH₂)_d-, where A is -O-, -S(O)_r-, and -NR⁷-;

m = 0, 1, 2 or 3; x is a whole number in the range 2-8; y is a whole number in the range 1-5; c is a whole number in the range 2-4; and r = 0, 1 or 2; d is a number in the range 0-5;

X and Y are independently selected from the group consisting of N, and CH;

Z and Z¹ can be the same or different, each being independently selected from the group consisting of N, CH and N(O);

B¹
cut
A²
R¹ and R² may each number 1-4 and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, polyhalolower alkyl, polyhalolower alkoxy, -OH, CN, NO₂, or COOR⁸;

R³ is selected from hydrogen, lower alkyl, lower alkoxy, hydroxyl, with the proviso that when n and k are both 0, then R³ is not -OH or alkoxy;

R⁴ is selected from the group consisting of hydrogen, lower alkyl, polyhalolower alkyl or -OH; and

R⁷ and R⁸ are independently selected from hydrogen, lower alkyl, substituted or unsubstituted phenyl; and substituted or unsubstituted benzyl, wherein said term "substituted" means optional substitution from one or more moieties selected from the group consisting of alkyl, alkoxy, -CF₃, halogen or aryl.

A³
Claim 4 (amended): The compound of claim 1, wherein p and q are independently 0 or 1.

A⁴
Claim 10 (amended): A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.





Please cancel Claim 11 without prejudice.

Please cancel Claim 12 without prejudice.


Please cancel Claim 14 without prejudice.

A⁵
Claim 16 (amended): A compound exhibiting H₃ antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:



B' cont



AS




Claim 17 (amended): A compound exhibiting both H₁ and H₃ antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:



B¹
cont

AS



Claim 19 (New Claim): The compound of claim 4, wherein Z is N, Z¹ is CH,
and p = q = 1.

Al₆